Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Janssen’s Imbruvica earns new NICE recommendation for leukaemia

Janssen’s Imbruvica earns new NICE recommendation for leukaemia

25th November 2016

Janssen's cancer drug Imbruvica has earned a new recommendation from the UK's National Institute for Health and Care Excellence (NICE).

The ibrutinib therapy, which has been included in the government's Cancer Drugs Fund scheme, will be made routinely available for NHS patients in England and Wales to treat chronic lymphocytic leukaemia based on this decision.

This ruling will offer access to a new therapy for an estimated 620 patients with chronic lymphocytic leukaemia who have had treatment before, or who have genetic variations known as 17p deletion or TP53 mutation.

Professor Carole Longson, director of the centre for health technology evaluation at NICE, said: "Patients with this type of leukaemia are difficult to treat; they have very limited treatment options available and some treatments can cause severe side effects."

This overturns previous guidance from NICE that did not recommend Imbruvica, with Janssen having since agreed to a reduction in price, leading the regulator's independent appraisal committee to deem the drug to be cost-effective.

The draft guidance is now open for consultation. If NICE's final guidance upholds this recommendation, the NHS must make it available within three months.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.ADNFCR-8000103-ID-801828942-ADNFCR

We currently have 10 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.